Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500084 · ClinicalTrials.gov registry record · Phase 3
Phase III ALTU-135 CP Safety Trial
A Phase 3 study, sponsored by Anthera Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT00500084 is a Phase 3 study that was terminated before completion, run by Anthera Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT00500084, a Phase 3 study, was terminated before completion, sponsored by Anthera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open-label, single-arm clinical study investigating the long-term safety of ALTU-135 treatment in Chronic Pancreatitis (CP) patients with exocrine Pancreatic Insufficiency (PI).
Interventions
- DRUG Liprotamase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500084
The ClinicalTrials.gov registry entry for NCT00500084 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liprotamase is the first listed.
NCT00500084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500084 about?
NCT00500084 is a clinical study titled "Phase III ALTU-135 CP Safety Trial". This is an open-label, single-arm clinical study investigating the long-term safety of ALTU-135 treatment in Chronic Pancreatitis (CP) patients with exocrine Pancreatic Insufficiency (PI).
What is the current status of trial NCT00500084?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2007-12. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00500084?
The interventions under investigation include: Liprotamase (DRUG).
Who is sponsoring clinical trial NCT00500084?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.